Post hoc analysis of the phase 3 BE MOBILE 1 and 2 trials in axial spondyloarthritis: male patients had better week-16 responses to bimekizumab vs placebo than females; females improved further by week 52, and inflammation fell similarly in both sexes.
Secondary analysis
Rudwaleit et al. Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE trials